Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tenecteplase thrombolysis

Phase 3Small molecule

XXuanwu Hospital, Beijing

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Basilar Artery OcclusionRecruiting

Acute Basilar Artery OcclusionPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Acute Basilar Artery Occlusion

NCT07203625

Clinical

Trials by Indication[1]

Acute Basilar Artery Occlusion1 trial

Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

Recruiting·XXuanwu Hospital, Beijing·Phase 4·NCT07203625·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tenecteplase thrombolysis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tenecteplase thrombolysis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tenecteplase thrombolysis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xuanwu Hospital, Beijing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXuanwu Hospital, Beijing

Related News